Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
about
PARP inhibitor treatment in ovarian and breast cancerIncorporating medical interventions into carrier probability estimation for genetic counseling.A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian CancerTriple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detectionPathogenesis, prevention, diagnosis and treatment of breast cancer.Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models.Morphological predictors of BRCA1 germline mutations in young women with breast cancer.Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registryBRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.Limited significance of family history for presence of BRCA1 gene mutation in Polish breast and ovarian cancer cases.Breast cancer risk-assessment models.Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved women.Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.Evaluation of models to predict BRCA germline mutations.Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction.Validity of models for predicting BRCA1 and BRCA2 mutationsGenetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.Management updates for women with a BRCA1 or BRCA2 mutation.Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO.Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.Establishing a program for individuals at high risk for breast cancer.Tumour morphology predicts PALB2 germline mutation status.PALB2 and breast cancer: ready for clinical translation!Developing Family Healthware, a family history screening tool to prevent common chronic diseases.Performance of BRCA1/2 mutation prediction models in Asian Americans.Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United StatesAbsence of germline BRCA1 mutations in familial pancreatic cancer patientsA method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family RegistryBRCA1/2 mutations and triple negative breast cancers.Assessing women at high risk of breast cancer: a review of risk assessment models.Pathology of hereditary breast cancer.Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features.Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO.Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis.
P2860
Q28741688-397DE639-F379-4703-99E8-E0BE10E7C0CFQ33279688-D5641AB2-F93C-48AE-9CC2-EE8BA18E0CF3Q33606561-EA75BF85-BE86-479E-80EB-A64D8F4F4715Q33739351-47E9DF7E-6554-48C3-AA15-01DC88E0D01AQ33853726-5BDEEBAE-DE41-4B81-8060-06B461D90B08Q34023647-F00AB312-065F-40B4-9A25-B6F34EE716E0Q34102617-0C1D4BB6-657E-4D3E-BEFE-2561D3660753Q34727284-BE8906C8-0BCE-455D-88EC-4D744F2D0B3DQ35029565-6D301168-6F95-4BC5-AC3A-1A1B8E34B0A9Q35050626-D85AEAFB-5C63-43BB-AC71-864C9EED19FBQ36064826-82894729-F5B3-4C7C-8243-178E17647308Q36394369-344270A1-19D4-4F2B-BDF3-CBE2E6A3B2DCQ36458723-36DF224D-341F-48E3-BA9E-D036E9D08EB9Q36464856-47C0D9CE-9EF0-48D8-8DA0-8E6C26146997Q36574427-50CECA11-4BB7-4067-B566-118FC7FA63A9Q36611734-81BADFB6-F6FE-48CE-89C9-AD91EE1A91A0Q36678625-70EB39AC-8A7E-40AA-9F57-DB14B5DDD762Q36711004-3B59542F-914C-4422-B250-302BD879B7ACQ36843211-347E7B7F-D3AA-42E6-9B8E-B172F47EDD5DQ36849977-259CCAE8-254B-444D-864D-1BC47317F812Q36926475-D5058EA7-402A-493A-A235-69665CABC5A0Q36955087-9E1CD546-C707-4B29-A07A-60D263E81051Q36983389-7BD25BE8-CBA6-400F-8ED6-A80A16F2771FQ37003285-6A2238D2-0C83-482E-A8C1-38D27DD1E97DQ37074279-38ABBBDC-4FF8-457B-A0C0-56CA0978ECC5Q37102032-F9250786-40E4-4160-8A1A-92D6618D0EE8Q37121713-C265A708-1524-4037-AA44-625DB2703A5EQ37155632-99F02D8F-95AD-4368-9FC7-2FE1DA6D6297Q37197715-2134DD9F-D453-4E6D-BFD4-417AD6BBCCC4Q37205554-F4793ACA-CD80-4AC1-A6B5-AE7D4E591615Q37252756-3C78A8B9-0F8C-4646-8F0B-4E6C87CEB0C7Q37407985-B79B9265-8D8E-48CA-ACBE-618F054564BEQ37739036-01189378-834C-44CA-AA45-F9FC8E3DDCDAQ37740949-30AA2730-8887-4BF8-AD75-5EEC5136E8B2Q41441053-2CFB3E3C-6688-4DA8-87C1-E219A9CB291EQ42443769-10D594B2-B2BD-42F0-8B51-8F69B90EA2F9Q42482668-0E73AE07-A2A2-476D-B791-038C72B0316CQ51280306-1F102380-11D5-4E0D-A580-2504BF955CE5Q51439738-53777540-7BD9-419B-AA3E-50374B020FA4Q51758191-C2C223E0-3AD3-4519-A371-1A46C1D98E28
P2860
Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Optimal selection of individua ...... mparison of available methods.
@ast
Optimal selection of individua ...... mparison of available methods.
@en
type
label
Optimal selection of individua ...... mparison of available methods.
@ast
Optimal selection of individua ...... mparison of available methods.
@en
prefLabel
Optimal selection of individua ...... mparison of available methods.
@ast
Optimal selection of individua ...... mparison of available methods.
@en
P2093
P356
P1476
Optimal selection of individua ...... mparison of available methods.
@en
P2093
Alvin Milner
Bickol N Mukesh
Clare Scott
Marion Harris
Mary-Anne Young
Paul A James
Rebecca Doherty
P304
P356
10.1200/JCO.2005.01.9737
P407
P577
2006-02-01T00:00:00Z